Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,550 shares of the medical research company’s stock after selling 182 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Bio-Rad Laboratories were worth $1,857,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Capital Advisors Ltd. LLC increased its position in Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares during the period. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Gladius Capital Management LP acquired a new position in Bio-Rad Laboratories during the third quarter worth $32,000. Headlands Technologies LLC purchased a new position in Bio-Rad Laboratories in the second quarter worth $51,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories in the third quarter valued at $55,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BIO has been the subject of a number of research analyst reports. Citigroup increased their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Royal Bank of Canada increased their target price on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a report on Monday, December 9th. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Stock Down 1.1 %

BIO stock opened at $336.28 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The company’s 50 day simple moving average is $341.35 and its 200-day simple moving average is $321.03. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99. The firm has a market capitalization of $9.41 billion, a PE ratio of -12.30 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. During the same quarter in the prior year, the firm earned $2.33 EPS. Bio-Rad Laboratories’s quarterly revenue was up 2.8% on a year-over-year basis. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.